• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

'Recovery' from chronic fatigue syndrome after treatments given in the PACE trial

Dolphin

Senior Member
Messages
17,567
I was wondering that however the oxford criteria are a conjunction of 4 things so if the research assessor decides that fatigue is no longer the main symptom or that fatigue is not present 50% of the time then a patient would not meet the Oxford criteria even with much lower scores and hence could be deamed recovered.
It might be worthwhile if one or more people write to PDW. I think I might be about the last person he would reply to, although still might try myself.
 

Firestormm

Senior Member
Messages
5,055
Location
Cornwall England
It must be a little bit embarassing for Esther Crawley as she claimed pace had a 40% recovery rate a while ago. So when they claim a 22% (15% above SMC) she has been shown to be wrong.

But then she promises her patients a 97% recovery rate.

I think this is very worrying. Also if 22% equates to 'moderately' effective it makes me wonder what on earth 'highly' effective might equate to.

Will perhaps find a link for that Crawley statement of 40%. It does seem to fly in the face of all the pomp and sensationalist headlines we were subjected to, doesn't it? I mean 22%. Hardly worth writing home about.

I am also very surprised that the DWP did not insist on an objective measure involving benefit withdrawal. Or some of the measures that we are subjected to in our work capability/disability assessments e.g. mobility components.

As with the PACE trial itself I am left thinking - especially with White's comments above - that this did not live up to expectations and hardly offered value for money given the expense and time consumption involved.

I still regard PACE as proving that whatever is responsible for this condition - generally - it can't be fixed by GET and CBT as some would have had us believe.

Still like other options they are a 'suck it and see' approach that may or may not prove helpful but should definitely not be oversold or sold unrealistically.

And what's with references to 'this episode of the illness'? I didn't get that one. It is suggestive of a 'recovery' being followed by a 'relapse'. But what recovery lasts 52 weeks? Or maybe when I read the paper it will show that I have misread this part of it.

What would be interesting would be the possibility of all treatments esp. drug treatments being compared along similar lines to those used in this paper. I mean if it is acceptable to them for GET and CBT and SMT and APT - then why not also for some of the drugs/treatments that are also available?

Have they unwittingly perhaps set a standard here? How might Ampligen for example stack up I wonder. Maybe the bar has been set now - too low perhaps - but set nonetheless. Beat PACE and you win.
 

user9876

Senior Member
Messages
4,556
And what's with references to 'this episode of the illness'? I didn't get that one. It is suggestive of a 'recovery' being followed by a 'relapse'. But what recovery lasts 52 weeks? Or maybe when I read the paper it will show that I have misread this part of it.
.

Recovery suggests a cure and hence would need a much longer follow up period to talk about in convincingly. I think for example that oncologists only ever talk about remission from cancer as they know that there is a high chance of it reoccuring at some point in the future - and they will do appropriate monitoring over 5+ years. I think they are actually making a sensible point that they cann't say that the recovery will last because they have only monitored patients for a year.

If people have recovered then a remission could be due to a fluctuation where symptoms are less or it could be due to, say, the immune system getting back to a normal equilibria but disease could reoccur if people are genetically subseptable to viral triggers breaking affecting the immune system in bad ways. This argument seems irrelivant to PACE since I think a recovery there is to down play symptoms and play up activities.
 

biophile

Places I'd rather be.
Messages
8,977
biophile

[satirical in part] Why would anyone object to a drug trial in which a number of patient were recruited at the start who could be redefined as recovered without any improvement or even some worsening from the drug, and then this was used to promote drug efficacy?

Indeed. We are such naughty misguided recalcitrants for not accepting the spin at face value.

Firestormm said:
As with the PACE trial itself I am left thinking - especially with White's comments above - that this did not live up to expectations and hardly offered value for money given the expense and time consumption involved. I still regard PACE as proving that whatever is responsible for this condition - generally - it can't be fixed by GET and CBT as some would have had us believe. Still like other options they are a 'suck it and see' approach that may or may not prove helpful but should definitely not be oversold or sold unrealistically.

The PACE results do not warrant a widespread rolling out of CBT and GET. However, if the pending paper on predictors and mediators reveals clues into which patients are more likely to benefit, that may help their targeting, although I will not be holding my breath after seeing http://www.trialsjournal.com/content/12/S1/A144 .

Also, good point about PACE lowering the standards for other treatments to compete. This would also include open-label Rituximab studies where patients taking it are told it is "powerful and safe"!
 

Firestormm

Senior Member
Messages
5,055
Location
Cornwall England
Well they don't target or offer anything - in PACE - for the severe/very severe patients of course. It would be interesting to see whether 'recovery' meshed with category e.g. did those in the 'mild' category benefit more from either or both therapies even using their own measures.

Is this the sort of thing you mean they are hoping to achieve? A means of saying such and such a patient or group will potentially find these therapies more beneficial? Maybe a psyche evaluation would help pre-treatment. I mean if a patient was for example more physically able, but was, for example, concerned adversely about returning to work, say, then they might theoretically benefit more from CBT.

I guess they will try to do this through statistical analysis but I am never solely convinced of this application in relation to therapies that cannot be subjected to more empirical measures. I am not able to understand that paper you link to, Bio. Above my abilities :)

Edit:

Given I have been writing about 'repeatedly, reliably and safely' in relation to benefit assessment; I wonder to what extent 'fluctuating' symptoms and debility was taken into account in PACE?
 

snowathlete

Senior Member
Messages
5,374
Location
UK
As they like Oxford definitions so much, let us take a look at how the Oxford Dictionary defines the word Recovery:

1. "a return to a normal state of health, mind, or strength"

Clearly, by using the word Recovery, but by redefining it to be below normal they are cheating and misleading their audience. The absolute shame of it.
 

Dolphin

Senior Member
Messages
17,567
I think this is very worrying. Also if 22% equates to 'moderately' effective it makes me wonder what on earth 'highly' effective might equate to.

Will perhaps find a link for that Crawley statement of 40%. It does seem to fly in the face of all the pomp and sensationalist headlines we were subjected to, doesn't it? I mean 22%. Hardly worth writing home about.

Evidence from a recent evidence trial of cognitive behavioural therapy and graded exercise therapy indicated a recovery rate of 30-40% one year after treatment [24].

from


The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study based on the CFS/ME national outcomes database.
BMC Health Serv Res. 2011 Sep 15;11:217. doi: 10.1186/1472-6963-11-217.
Collin SM, Crawley E, May MT, Sterne JA, Hollingworth W; UK CFS/ME National Outcomes Database.
http://www.biomedcentral.com/1472-6963/11/217

She was corresponding author
 

Research 1st

Severe ME, POTS & MCAS.
Messages
768
Lets compare the medical therapy performance of the hugely expensive UK's Wessley School PACE trial vs a biomedical CFS drug trial:

Result:

PACE trial = 22% improvement.
Chemotherapy drug trial for CFS = 67% improvement. *

* Source:
Fluge et al, 2011.
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.
PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.


Perhaps from the startling contrast in therapy outcome we can see the end of psychiatry and psychological chronic fatigue misrepresenting ME CFS is near? Finally there could be potentially effective and superior treatments on the near horizon to psychiatric accusations of 'faulty illness beliefs'. That's if if Rituximab research is to be permitted to continue without state interference (no funding).

We need to spread the word that cancer drug therapy in CFS is around 3x more effective than psychotherapy
in people without. Meanwhile, organic CFS patients like Robert Miller are so desperate for help that is denied by the CDC and FDA, they're on hunger strike as we speak! That is pretty shocking.

First rule of medicine, do listen to your organically ill CFS ME patient. Don't listen to people who aren't studying your patients (psychological tiredness) whilst erroneously claiming they are i.e the PACE trial and allied psychiatric 'fatigue' research that has terrible treatment outcomes using CBT & GE and relapses ME patients, permanently in some cases.
I should also add there is at least one case of an ME patient who died after engaging in an NHS graded exercise programme, a therapy which the Wessely school insist is safe. :mad:

What an awful situation this all is, and unjustly caused by people who ignore biomedical CFS research spanning near decades. What will the CDC and Dr Unger do about this? Continue their five year chronic fatigue psychobehavioural approach and continue telling people with organic CFS to gently exercise themselves better to health?

Think how stupid this all is and how costly in terms of human suffering.

If altering thoughts and beliefs about the causes and maintainers of CFS was effective for treating CFS, then why does the Rituximab paper (which ignored thoughts and beliefs) have a three fold better outcome than psychotherapy?

Answer: organic CFS and ME are not psychological disorders but contain a disease process that needs medical treatment with immunotherapy drugs.
 

Dolphin

Senior Member
Messages
17,567
The following paper that is referenced in the recovery paper is available for free at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020067/

I haven't read it yet but I suspect the points White et al. make that reference this paper are very questionable



Ascertaining the size of the symptom iceberg in a UK-wide community-based survey.

Br J Gen Pract. 2011 Jan;61(582):e1-11. doi: 10.3399/bjgp11X548910.

McAteer A, Elliott AM, Hannaford PC.

Source
Centre of Academic Primary Care, University of Aberdeen, Aberdeen. a.mcateer@abdn.ac.uk

Abstract*

BACKGROUND:

The symptom iceberg describes the phenomenon that most symptoms are managed in the community without people seeking professional health care.

The size of the iceberg for many symptoms is unknown, as is their association with personal characteristics, including history of a chronic disease.

AIM:

To ascertain the size of the symptom iceberg in the UK.

DESIGN OF STUDY:

A UK-wide community-based postal survey.

SETTING:

Urban and rural communities across the UK.

METHOD:

A postal survey was sent to an age- and sex-stratified random sample of 2474 adults, aged 18-60 years, drawn from 20 practices around the UK.

Questions were aimed at investigating adults' experiences of 25 different symptoms in the previous 2 weeks.

RESULTS:

The number of symptoms experienced by one individual in the previous 2 weeks ranged from 0 to 22 (mean 3.66).

Of the symptoms examined, the three most common were: feeling tired/run down; headaches; and joint pain.

Univariate analysis found symptom prevalence to be significantly associated with a wide range of participant characteristics.

However, after adjustment, many of these associations no longer remained significant for a number of the symptoms.

Presence of a chronic condition, age, and employment status were the three factors most commonly associated with the 2-week prevalence of symptoms.

Reported symptom characteristics (severity, duration, interference, and time off work) varied little by sex or age.

CONCLUSION:

Symptoms in the UK community are common.

Symptom prevalence was associated with a number of participant characteristics, although the extent of this association was less than has been reported in previous research.

This study provides an important current baseline prevalence of 25 symptoms in the community for those who do, and do not, have a chronic condition.

*I gave each sentence its own paragraph.
 

alex3619

Senior Member
Messages
13,810
Location
Logan, Queensland, Australia
Lets compare the medical therapy performance of the hugely expensive UK's Wessley School PACE trial vs a biomedical CFS drug trial:

Result:

PACE trial = 22% improvement.
Chemotherapy drug trial for CFS = 67% improvement. *

* Source:
Fluge et al, 2011.
Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.
PLoS One. 2011;6(10):e26358. doi: 10.1371/journal.pone.0026358. Epub 2011 Oct 19.

Answer: organic CFS and ME are not psychological disorders but contain a disease process that needs medical treatment with immunotherapy drugs.

Don't forget this was a preliminary result. I suspect its now over 70%, but we will find out when the final paper is released.
 

Research 1st

Severe ME, POTS & MCAS.
Messages
768
I hope you mean Doctor Fluge and colleagues Alex. :lol:

Yes I would imagine that if they can use an immunological biomarker to select candidates who will be likely 'responders' (due to on-going experience in observing +/- outcomes from administering the drug) then the percentage rates of 'improvement' from CFS symptoms should indeed increase above 67%. Very good point.
 

Dolphin

Senior Member
Messages
17,567
(Minor) good news:
There doesn't seem to be any word or reference limit for Psychological Medicine: the guidelines don't mention them and I have gone through all the letters published in 2012 (excluding "research letters" i.e. which present new data) - all 2012 issues of the journal can be see for free for the next 5 weeks or so.
I'll try to give some more information on the numbers when I read the letters (one or two may be more research-type letter when I read them).
Probably still best to be under 500 words and, say, 13 references.
 

Research 1st

Severe ME, POTS & MCAS.
Messages
768
Remember this old chestnut?

'There is no evidence that GET (with or without CBT) actually increases activity levels. Where objective measures have been employed, the increments in activity levels have been negligible and no greater than that seen in controls'.

Source: British Psychological Society submission to the NICE Guideline Development Group, 2006
 

Dolphin

Senior Member
Messages
17,567
This is a link to the 12MB file of the full PACE Trial Protocol, obtained using a FOI request as I understand it. It includes the exact questionnaires used e.g. for CFS and ME criteria, physical functioning, fatigue, etc. - having such info makes it much easier to understand such studies.

People should be able to download it for free.

http://www.mediafire.com/view/?92x9s920bsftyx0

Alternative download link: http://www.yousendit.com/download/UW16K0drdGo4Q1JsQXNUQw (this lasts for a maximum of 100 downloads and 7 days)
A more permanent home has now been found for this 12 MB file: http://evaluatingpace.phoenixrising.me/PACE_Protocol.pdf
 
' Objective measures of physical activity have been found previously to correlate poorly with self-reported outcomes (Wiborg et al. 2010),' Hmmm - because self-reported outcomes were found to exaggerate increased activity as against objective measures (actometer) So the obvious thing was to drop the use of the actometer and rely only on self-reports. This apparently is an example of the commitment to 'science' for which a knighthood was recently conferred.
Then there is the '33% depressed'. One day I will attempt a full analysis of the questionnaires used to diagnose depression, but it won't surprise anyone that on the Beck Inventory, for example, the 'physical' signs of 'depression' include fatigue, cognitive problems and disturbed sleep patterns..... Having worked in the field of mental health since 1971, I believe that I can reliably distinguish 'not feeling like doing anything' (apathy, low mood) - depression - from 'desperate to do things and when I try and find I can't, I get really upset' - ME. That's how hard it is to make a 'differential diagnosis'. But if you put ME symptoms on a list for diagnosing depression, it makes it a lot easier to claim that ME people are suffering from 'depression'. Mind you, being this sick for so long is a bit depressing, but there's nothing neurotic about that!
 

biophile

Places I'd rather be.
Messages
8,977
Depending on measures of improvement (lower is better for Number Needed to Treat) ...

PACE Trial: 22% vs 8%. 40% vs 25%, ~75% vs ~60%. NNT = 7 (non-blinded).

Rituximab: 67% vs 13%. 60% vs 7%. NNT = 2 (double-blinded).

Do not forget that the Rituximab trial, while a small preliminary study with limited outcome measures, was also double-blind. PACE was non-blinded, and the mere act of admitting that blinding would have been impractical, does not make the complications of open-label trials magically disappear, particularly when the authors are focusing exclusively on self-reported symptoms of limited correlation while actively ignoring employment status, physical activity levels, walking distances, welfare receipts, etc, in their definitions of improvement and (*cough*) complete "recovery" (*cough*). Even worse, the PACE data on the latter measures looks very stark, and contradicts notions of recovery.

White et al said:
The NNT of 7 for recovery after both CBT and GET is within the range of the effects found for drug treatments in both general medical and psychiatric conditions (Leucht et al. 2012).

NNT is dependent on the response size being measured. Furthermore, Leucht et al are reporting on placebo-controlled drug trials for medical and psychiatric conditions, some of which had much larger effect sizes than CBT and GET in PACE, where the net response rate required to get a NNT of 7 is also well within the range of a placebo response, being a non-blinded trial with different levels of encouragement and optimism between groups. That said, personally I doubt it would explain all improvement. However, it is a serious problem if therapies specifically aimed at changing patients' "unhelpful" beliefs and perceptions and behaviours are altering questionnaire-taking behaviour beyond what is actually happening.

White et al said:
Although only 22% recovered after either CBT or GET, if different participants recovered after CBT than after GET, then the proportion recovering after either treatment would be larger than 22%, but not larger than 39%.

Interesting argument, there may be some overlap. Perhaps we could do a trial of all substances indicated to help CFS, and just add up all figures too for a hypothetical 200% success rate!
 
And just to add to Dolphin's list of interesting sites, there is the King's College CFS information for patients and practitioners. (The one for practitioners urges people performing CBT to try to look beyond their protocols and at the patient's actual situation, or 'what some analysts refer to as 'The Real'. A truly radical proposal.)

But even more exciting is the information contained in the advice to patients concerning 'The Physiology of CFS'. This begins with a list of the various physiological changes observed in people with CFS/ME, which leads the reader to think that, finally, they're acknowledging the physiological nature of this illness. But it turns out that every single one of these factors is caused by resting! (or may be, or probably is, or something very similar has been). It is particularly notable that when healthy subjects go to bed for three weeks, these symptoms appear, and when they get up again, these symptoms go away. The message is obvious: resting is a dangerous activity, while the curative potential of 'not resting' has yet to be fully explored. I don't know why this very important information, with its broad implications for both medical practice and everyday life, has been hidden away in an article about CFS.

It states that the article is 'based on the work of Pauline Powell'. I looked her up, and she has, indeed, written a number of articles making these assertions, but I didn't see any research papers.
 

biophile

Places I'd rather be.
Messages
8,977
Firestormm.

Re: severely affected. Obviously not covered by published evidence and the FINE Trial was a failure, but IIRC Wessely has claimed that his clinic get good results in the severely affected too, and the PACE manuals claim that the GET model should apply equally or even more in severely affected patients. Wessely has also said about bedridden patients: "In that kind of disability psychological factors are important and I don’t care how unpopular that statement makes me." So, severely affected patients are only sometimes spared having CBT/GET pushed on them because of the lack of published evidence, not because CBT/GET proponents do not want to treat them or do not actually treat them in practice.

Re: targeting. CBT and GET only help a minority of Oxford criteria patients report modest improvements in some measures but not others. CBT/GET proponents admit to not knowing enough about what predicts and mediates the response, but there is still a wide application, all patients are encouraged to attempt it. Knowing more about what predicts and mediates the response may help to determine which patients need it and what aspects of therapy work best.
 

Esther12

Senior Member
Messages
13,774
I was wondering that however the oxford criteria are a conjunction of 4 things so if the research assessor decides that fatigue is no longer the main symptom or that fatigue is not present 50% of the time then a patient would not meet the Oxford criteria even with much lower scores and hence could be deamed recovered.

Or maybe the SF36 PF or Chalder Fatigue Score meant that their criteria for Oxford did not apply, even if the patient still fulfilled the other parts of the criteria.


I'm interested by the fact that this got so little press, as generally Science Media Centre stuff does. I wonder if journalists were scared of militant CFS patients? Or were they left wondering 'Didn't I report that this study showed a recovery rate of 1/3 two years ago?'

There have been little bits on-line. I like the opening paragraph for this:

Recovery from Chronic Fatigue Syndrome Possible

By Rick Nauert PhD Senior News Editor
Reviewed by John M. Grohol, Psy.D. on February 1, 2013
Recovery-from-Chronic-Fatigues-Syndrome-is-Possible-SS1.jpg
New research discovers it is possible to recover from chronic fatigue syndrome (CFS), if an individual is willing to participate in therapy addressing mental and physical well-being.
Researchers from Queen Mary, University of London, have found that cognitive behavior therapy (CBT) and graded exercise therapy (GET), as supplements to specialist medical care, increase the likelihood of recovery from CFS three-fold compared to other treatments studied.
Research results are published in the journal Psychological Medicine.
Chronic fatigue syndrome is a long-term and debilitating condition that affects around 250,000 people in the UK and at least one million Americans.
Symptoms include profound physical and mental fatigue (characteristically made worse by exertion), muscle and joint pain, disturbed sleep and both concentration and memory problems.
In the new study, researchers followed 640 participants with CFS who were randomized into one of four treatment groups:
  • Specialist medical care (SMC) alone;
  • SMC plus adaptive pacing therapy (APT);
  • SMC plus cognitive behavioral therapy (CBT);
  • SMC plus graded exercise therapy (GET)
Evidence for recovery was assessed one year after participants were randomly allocated to treatments.
Previous published results showed that both CBT and GET led to greater reductions in symptoms and disability than either APT or SMC.
In the current analysis, researchers have gone a step further and examined how many patients had recovered from their illness after these treatments.
Patients were classed as recovered if they no longer met several criteria for ill health which were initially used to define eligibility for the trial. These included not suffering from significant fatigue or physical disability, and no longer meeting diagnostic criteria for CFS.
Patients also had to rate themselves as being “much” or “very much better” in their overall health.
The findings showed that those who received CBT or GET, in addition to SMC, were three times more likely to meet the criteria for recovery than those receiving SMC alone or in combination with APT.
Overall 22 per cent of those who received either CBT or GET, in addition to SMC, met the criteria for recovery, compared to eight per cent after APT in addition to SMC, and seven per cent after SMC alone.
There were similar patterns of recovery however CFS was defined, including those who were diagnosed as having myalgic encephalomyelitis (ME), thought by some to be the same as CFS and by others as being different.
Peter White, Professor of Psychological Medicine at Barts and the London School of Medicine and Dentistry, part of Queen Mary, was the lead co-principal investigator of the PACE trial and co-author of the latest paper.
Lead co-principal investigator Peter White commented:
“This is good news and shows that recovery from this debilitating condition is possible for some patients. We now need to go further to understand why only a relatively small proportion of patients recover, which shows how much this condition varies between individuals; one treatment is unlikely to work for everyone.
“Some people may question the use of the term ‘recovery’, and how to define when a patient is ‘recovered’ was a key issue we faced. We focused on recovery from the current episode of the illness and used several measures of both symptoms and disability to give us the most complete picture possible. Further analysis is needed to see if recovery is sustained in the long-term.”
The other co-author of the paper, Professor Michael Sharpe, continues: “The rehabilitative treatments of CBT and GET for CFS have been controversial. This analysis of the current trial data shows that not only do they achieve improvements in the majority, but that they can also lead to recovery in a substantial minority.”
Experts are enthused with the finding that people can recover from chronic fatigue syndrome. “Healthcare professionals can now be more confident in sharing this possibility with patients, many of whom are understandably concerned about their future.”
Source: Queen Mary, University of London

http://psychcentral.com/news/2013/02/01/recovery-from-chronic-fatigue-syndrome-possible/51060.html

This bit from Queen Mary is good too:

Patients were classed as recovered if they no longer met several criteria for ill health which were initially used to define eligibility for the trial. These included not suffering from significant fatigue or physical disability, and no longer meeting diagnostic criteria for CFS.

If that is their definition of 'significant fatigue or physical difficulty', then we can say quite confidently that CBT and GET do not lead to significant reductions in fatigue or disability.